The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole)
-
Surgery alone (Pooled-analysis)
Patients with stage II and III colon cancer
Gastrointestinal Cancers
Colon Cancer
-
-
A
ADJUSTMENTS
FINAL SCORE
F1
1
5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole)
-
Surgery alone (Meta-analysis)
Patients with resected stage II and III colon cancer
Gastrointestinal Cancers
Colon Cancer
-
-
A
ADJUSTMENTS
FINAL SCORE
F1
1
5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole)
-
Surgery alone (Meta-analysis)
Patients with resected stage II and III colon cancer
Gastrointestinal Cancers
Colon Cancer
-
-
A
ADJUSTMENTS
FINAL SCORE
F1
1
5FU/LEV (5-fluorouracil + levamisole)
-
Levamisole
Resected stage III (Dukes stage C) colon cancer
Gastrointestinal Cancers
Colon Cancer
-
Intergroup 0035
A
ADJUSTMENTS
FINAL SCORE
F1
1
Tivozanib
-
Sorafenib
Adult patients with relapsed or refractory advanced RCC following ≥2 prior systemic therapies
Genitourinary Cancers
Renal cell cancer
-
TIVO-3
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Enzalutamide
ADT (androgen deprivation therapy)
Placebo + ADT
For the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy
Genitourinary Cancers
Prostate cancer
-
ARCHES
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Lorlatinib
-
Crizotinib
Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive (NSCLC) previously not treated with an ALK inhibitor
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
CROWN
4
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
2
Sacituzumab govitecan-hziy
-
Physician’s choice of single agent ChT
Treatment for adult patients with metastatic triple-negative breast cancer who received at least two or more prior therapies, at least one of them for advanced disease
Breast Cancer
Breast Cancer
Triple-negative
ASCENT
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Nivolumab
Cabozantinib
Sunitinib
First-line treatment of adult patients with advanced RCC
Genitourinary Cancers
Renal cell cancer
-
CheckMate-9ER
1
PRELIMINARY SCORE
OS
8
ADJUSTMENTS
FINAL SCORE
F1
5
Atezolizumab
-
Single arm (Phase II)
Single-arm study of atezolizumab in patients with locally advanced or metastatic urothelial bladder cancer
Genitourinary Cancers
Urothelial Carcinoma
-
IMvigor210 (Cohort 2)
1
PRELIMINARY SCORE
OS
8
ADJUSTMENTS
FINAL SCORE
F1
5
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Treatment Setting
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
esmo.mcbs.table.heading.visualisation
esmo.mcbs.table.heading.visualisation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.